Omalizumab in severe asthma and food allergies with IgE levels >1500 kU/L: Two-year evaluation
Pediatr Allergy Immunol
.
2023 Dec;34(12):e14057.
doi: 10.1111/pai.14057.
Authors
Giulio Dinardo
1
,
Arianna Cafarotti
2
,
Francesca Galletta
3
,
Alessandro Fiocchi
2
,
Stefania Arasi
2
Affiliations
1
Department of Woman, Child and of General and Specialized Surgery, University of Campania Luigi Vanvitelli, Naples, Italy.
2
Allergy Diseases Research Area, Pediatric Allergology Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
3
Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', Pediatric Unit, University of Messina, Messina, Italy.
PMID:
38146110
DOI:
10.1111/pai.14057
No abstract available
MeSH terms
Anti-Asthmatic Agents* / therapeutic use
Asthma* / drug therapy
Food Hypersensitivity* / drug therapy
Humans
Immunoglobulin E
Omalizumab / therapeutic use
Substances
Omalizumab
Immunoglobulin E
Anti-Asthmatic Agents